Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF AVELUMAB (MSB0010718C) ALONE OR IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN ALONE IN PATIENTS WITH PLATINUM-RESISTANT/REFRACTORY OVARIAN CANCER
Brief Summary: A Phase 3 global study comparing avelumab alone to avelumab plus PLD and to PLD alone to demonstrate that avelumab given alone or in combination with PLD is superior to PLD alone in prolonging Overall Survival in patients with platinum resistant/platinum refractory ovarian cancer.


Options:
A: Arm Label: Placebo + Carboplatin + Paclitaxel -> Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Other: Placebo to Veliparib | Arm Label: Veliparib + Carboplatin + Paclitaxel -> Placebo; Type: EXPERIMENTAL; Interventions: Drug: Veliparib, Drug: Paclitaxel, Drug: Carboplatin, Other: Placebo to Veliparib | Arm Label: Veliparib + Carboplatin + Paclitaxel -> Veliparib; Type: EXPERIMENTAL; Interventions: Drug: Veliparib, Drug: Paclitaxel, Drug: Carboplatin | Intervention Type: DRUG; Name: Veliparib; Assigned to Arm(s): Veliparib + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Veliparib | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Placebo + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Veliparib | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Placebo + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Veliparib | Intervention Type: OTHER; Name: Placebo to Veliparib; Assigned to Arm(s): Placebo + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Placebo
B: Arm Label: avelumab; Type: EXPERIMENTAL; Interventions: Biological: avelumab | Arm Label: avelumab plus pegylated liposomal doxorubicin (PLD); Type: EXPERIMENTAL; Interventions: Biological: avelumab, Drug: PLD | Arm Label: PLD; Type: ACTIVE_COMPARATOR; Interventions: Drug: PLD | Intervention Type: BIOLOGICAL; Name: avelumab; Assigned to Arm(s): avelumab, avelumab plus pegylated liposomal doxorubicin (PLD) | Intervention Type: DRUG; Name: PLD; Assigned to Arm(s): PLD, avelumab plus pegylated liposomal doxorubicin (PLD)
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: olaparib, Drug: paclitaxel, Drug: Drug: carboplatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: paclitaxel, Drug: carboplatin | Intervention Type: DRUG; Name: olaparib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Drug: carboplatin; Assigned to Arm(s): 1
D: Arm Label: olaparib + cediranib; Type: EXPERIMENTAL; Interventions: Drug: olaparib+cediranib combination therapy | Arm Label: durvalumab + olaparib; Type: EXPERIMENTAL; Interventions: Drug: durvalumab + olaparib combination therapy | Arm Label: durvalumab + chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: durvalumab + chemotherapy treatment | Arm Label: durvalumab + tremelimumab + chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: durvalumab + tremelimumab + chemotherapy treatment | Arm Label: durvalumab + tremelimumab + paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: durvalumab + tremelimumab + paclitaxel treatment | Arm Label: durvalumab +chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: durvalumab +chemotherapy treatment | Intervention Type: DRUG; Name: olaparib+cediranib combination therapy; Assigned to Arm(s): olaparib + cediranib | Intervention Type: DRUG; Name: durvalumab + olaparib combination therapy; Assigned to Arm(s): durvalumab + olaparib | Intervention Type: DRUG; Name: durvalumab + chemotherapy treatment; Assigned to Arm(s): durvalumab + chemotherapy | Intervention Type: DRUG; Name: durvalumab + tremelimumab + chemotherapy treatment; Assigned to Arm(s): durvalumab + tremelimumab + chemotherapy | Intervention Type: DRUG; Name: durvalumab + tremelimumab + paclitaxel treatment; Assigned to Arm(s): durvalumab + tremelimumab + paclitaxel | Intervention Type: DRUG; Name: durvalumab +chemotherapy treatment; Assigned to Arm(s): durvalumab +chemotherapy

Answer: B